Related Experiment Video
Updated: May 6, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
Adherence to dual antiplatelet therapy: can we do better?
Srinivas Yallapragada1, Saifullah Siddiqui, Ryan Gindi
1Division of Cardiology, University of Illinois at Chicago, IL, USA.
Expert Review of Cardiovascular Therapy
|October 22, 2013
Summary
Improving medication adherence for dual antiplatelet therapy after percutaneous coronary intervention is crucial. This review highlights the importance of this therapy, the consequences of stopping it early, and strategies for better patient compliance.
Area of Science:
- Cardiology
- Pharmacology
- Health Services Research
Background:
- Medication adherence remains a significant challenge for patients post-percutaneous coronary intervention (PCI).
- Non-compliance with dual antiplatelet therapy (DAPT) is alarmingly high.
- Current management strategies have not evolved to address this critical issue.
Purpose of the Study:
- To underscore the vital role of dual antiplatelet therapy (DAPT) in patients undergoing PCI.
- To examine the clinical and economic consequences of premature DAPT discontinuation.
- To propose actionable strategies for enhancing medication adherence.
Main Methods:
- Literature review focusing on DAPT adherence post-PCI.
- Analysis of clinical outcomes associated with non-adherence.
- Examination of economic impacts of treatment failure.
- Synthesis of evidence-based strategies for improving adherence.
Main Results:
- Premature DAPT discontinuation is linked to increased risks of stent thrombosis and major adverse cardiovascular events.
- Poor adherence incurs substantial healthcare costs due to recurrent cardiovascular events and rehospitalizations.
- Several patient-centered and system-level strategies show promise for improving adherence.
Conclusions:
- Optimizing DAPT adherence is essential for long-term patient outcomes after PCI.
- Addressing the clinical and economic burdens of non-adherence requires innovative management approaches.
- Future interventions should focus on personalized strategies to support patients in adhering to DAPT regimens.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:27Coronary Artery Disease V: Interprofessional Care
452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
01:27Peripheral Artery Disease III: Interprofessional Care
659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
01:26Angina IV: Management
496
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
496
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482